Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

They are too big to enter the cells they need to treat. A new approach from Duke engineers could change that by using ...

A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials.

Researchers at the University of Colorado Anschutz may have identified why many cancer patients say food suddenly tastes ...

Weight-loss drugs have been found to dramatically slash death rates in colon cancer patients, according to new research. Patients taking GLP-1 receptors - the class of drugs behind Ozempic, Wegovy and ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...